The urokinase receptor (uPAR) is composed of three homologous domains based on disulfide spacing. The contribution of each domain to the binding and activation of single chain urokinase (scuPA) remains poorly understood. In the present paper we examined the role of domain II (DII) in these processes. Repositioning DII to the amino- 
Introduction
Urokinase type plasminogen activator (uPA) has been implicated in angiogenesis, wound healing, fibrinolysis and formation of tumor metastases. The capacity of uPA to promote remodeling of clots and basement membrane through its enzymatic activity and to promote cell adhesion through non-enzymatic processes are both modulated by its interaction with its cellular receptor, uPAR 1 . The interaction between the uPA/uPAR complex and β-integrins has been implicated in cell adhesion and migration 2, 3 . uPAR -/-mice exhibit defective leukocyte recruitment to inflamed peritoneum due to impaired cell adhesion 4 . uPAR-dependent signaling has also been implicated in various signal transduction events, cell differentiation and tumor dormancy [5] [6] [7] [8] [9] [10] [11] . uPAR can be expressed on the surface of many but not all cell types as a 281 amino acid, three domain, glycosylphosphatidylinositol (GPI) linked protein 12 . Each domain consists of 81-87 amino acids that are characterized by a generally conserved pattern of cysteine residues, which are separated from each other by ~11 amino acids linker sequences. There is ~20% amino acid sequence similarity among the domains at the amino acid level 13 . However, the mechanism by which the three domains interact to generate a high affinity binding site for uPAR and participate in cell adhesion and scuPA activation remains largely unresolved.
We 14 and others 15, 16 have reported that scuPA binds to soluble domain I of uPAR (sDI), albeit with ~50 fold lower affinity than to full length suPAR or GPI-linked uPAR by guest on http://www.jbc.org/ Downloaded from -4 -and with even lower affinity to a soluble fragment composed of domains II and III (sDII/DIII) 14 . In addition, each fragment of suPAR displays less capacity to activate scuPA than the intact receptor 14 . Proteolytic cleavage of uPAR between the DII and DIII generates a soluble fragment composed of DI and DII that binds uPA with an affinity similar to that of isolated sDI 16 . Thus, the connection between the domains of suPAR is essential to generate a high affinity site. The fragment containing DII and DIII may come into close proximity to DI to form an extended binding site for uPA 17 . Alternatively, DII and DIII may contain auxiliary binding sites that are independent of the site within DI.
Potential contact sites for uPA on the surface of sDI and sDIII have been probed using mutagenesis, chemical protection and cross-linking approaches [17] [18] [19] [20] , but direct contact between these portions of uPAR and uPA itself have not been proven.
Furthermore, the contribution of domain II within the intact receptor to uPA binding has received little attention 21 . The studies reported here identify a region in domain II composed of 9 amino acids that is required for scuPA to bind full-length uPAR with high affinity. Mutation of three arginine residues within this region of uPAR reduces the affinity of scuPA binding to a level comparable to that of domain I alone, and abolished the capacity of suPAR to activate scuPA in the absence of amino acid substitutions in domain I or domain III. These results demonstrate that domain II is required for high affinity binding of scuPA to uPAR.
by guest on http://www.jbc.org/ Downloaded from -6 -After the nucleotide sequence of each final construct was confirmed, COS cells were transfected using lipofectin. Expression levels of uPAR were measured by ELISA using polyclonal anti-uPAR antibody. Binding of anti-uPAR and scuPA to cells expressing each variant were demonstrated to be >90% PI-PLC sensitive. Specific binding of 125 IscuPA to these transiently transfected cells was measured as described below. All injections were performed using the RANDOM command in the automated method.
Mutagenesis of uPAR domain II.
Binding of scuPA was measured using two fold dilutions over a range of concentrations (12.5 nM -0.2 nM for WT-scuPA, 50 nM to 0.4 nM for m2A-suPAR, 200 nM to 12.5 nM for m3A-suPAR, and 400 nM to 25 nM for m5A-suPAR). Data, collected at 2.5 Hz, were fit to a 1:1 Langmuir reaction mechanism using global analysis in the BIA evaluation 3.0 software (Biacore, AB, Sweden). Secondary plots of the data [ln(|dR/dt|)
vs t] were also performed to unmask any contribution of mass transport to the kinetic data.
Activation of scuPA by suPAR variants. The capacity of suPAR variants to promote scuPA-mediated plasminogen activation was measured using a chromogenic assay, as 
Results

Binding of scuPA to uPAR requires interdomain cooperativity.
There is considerable indirect evidence to suggest that each domain of uPAR contributes to the development of the high affinity binding site for scuPA. The purpose of our studies was to study the specific contribution of DII to this process. To begin to address this question, we measured the specific binding of Of interest, this region in DII (R 137 -R 145 ) occupies a similar position with respect to the cysteine residues to the regions in domains I and III that also have a high probability of surface expression and have previously been implicated in scuPA binding 13, 17, 19, 20 .
Therefore, we targeted this region to examine the role of DII in scuPA binding and interdomain cooperativity.
Mutations in domain II of suPAR (R 137 -R 145 ) regulate the binding of scuPA.
To examine the role of this region in DII, we generated wild-type suPAR in S2 cells as well as a suPAR variant, designated m5A, in which five charged amino acids within this region (R 137 , K 139 , R 142 , H 143 and R 145 ) were mutated collectively to alanine.
To characterize the binding affinity of m5A-suPAR, we first examined the capacity of the purified protein to inhibit the binding of 125 I-wild type suPAR (10 nM) to a previously characterized CHO cell line that expresses high levels of GPI-anchored scuPA ( Figure 3 , Figure 3 , Table I ). In contrast, m3A-suPAR (IC 50 ~2.6 µM) and m5A suPAR (IC 50 ~16 µM) were comparatively much weaker competitors.
To confirm these results and to obtain a more precise estimate of their Kds, we measured the binding of scuPA to immobilized WT-and each variant suPAR in real time as surface plasmon resonance (Table II) . Binding of scuPA to immobilized WT-suPAR from S2 cells was essentially identical to the Kd measured using suPAR expressed in mammalian cells (not shown) and comparable to the affinity for GPI-anchored uPAR.
m2A-suPAR bound scuPA with a 4-5 fold lower affinity, attributable primarily to an increase in "off-rate". In contrast, the affinity of scuPA for m3A-suPAR was ~100-fold lower than was seen with WT-suPAR due to a ~10 fold reduction in the apparent "on rate" and a 6 fold increase in the "off-rate" (Table II) . The decrease in the affinity of m5A-uPAR was even greater (~160 fold), suggesting a contribution from all five charged residues. Interestingly, the apparent "off-rate" of scuPA from m5A-suPAR was similar to that of WT-suPAR, whereas the apparent "on-rate" was even slower than to m3A- -17 -suPAR. These data suggest a complex interaction among these 5 residues and/or with other regions of uPAR
Binding of scuPA to GPI linked suPAR mutants
To re-evaluate these observations in a more physiologic setting, we examined the effect of these mutations in DII on the function of cellular, GPI-anchored receptors. To do this, we generated stable cell lines expressing wild type receptor and each of the three DII variants. As mentioned above, 125 I-scuPA bound specifically to WT-uPAR with a Kd = 0.91 ± 0.51 nM (mean ± SD, n=4). scuPA bound to cells expressing m2A-uPAR with a comparable affinity (Kd = 1.96 ± 0.97), whereas binding to m3A-uPAR and m5A-uPAR were each greatly reduced (>40 nM) ( Figure 4 , Table III (Table III) . 
Activity of suPAR variants
Binding of scuPA to its receptor promotes its enzymatic activity [27] [28] [29] . We therefore examined the capacity of each suPAR variant to promote the plasminogen activator activity of scuPA. A fixed concentration of scuPA (5 nM) was incubated with each variant over a wide range of receptor concentrations, including concentrations well in excess of their respective Kds as determined by surface plasmon resonance.
Plasminogen activation was determined 60 minutes after the incubation was started. WTsuPAR generated in S2 cells stimulated scuPA activity in a dose-dependent and saturable manner, consistent with our findings using mammalian suPAR 24 . m2A-suPAR stimulated scuPA enzymatic activity less effectively than did WT-suPAR (EC 50 ~100 nM vs. 20 nM for WT-suPAR). The decrease in m2A-suPAR activation was proportional to the reduction in its affinity for scuPA ( Figure 5 ). In contrast, neither m5A-nor m3A-suPAR promoted significant scuPA-mediated plasminogen activation even when the receptor was present at 500 nM final concentration, i.e. ~10 times greater than its Kd measured by surface plasmon resonance ( Figure 5 ).
Effect of mutations in domain II on inter-domain cooperativity.
The observation that m5A-suPAR binds scuPA with a Kd of 55 nM, a value comparable to the affinity of isolated sDI 14 , may indicate that these mutations interrupt a binding epitope in DII-DIII and/or disrupt the ability of the three domains to interact in a productive conformation. To begin to examine the mechanism by which these mutations 20 . Upon photoactivation, these groups cross-link to domain I or to domain III, respectively. AE-68 tagged on either end of the peptide showed comparable incorporation into WT-suPAR and m5A-suPAR, excluding a direct effect of the mutations on scuPA binding sites in DI, and indicating that the proximity of these regions in DI and DIII to each other was retained in the mutant.
sDI can interact with sDII-DIII, and this interaction enhances the affinity of scuPA binding 14 . Therefore, we next asked whether the mutations introduced into the second domain of uPAR affects its interaction with domain I. To do so, we first generated stable cell lines expressing WT-and m5A-DII-DIII as GPI-anchored proteins.
Again, clones were chosen for comparable levels of cell surface receptor expression by FACS and ELISA. sDI increased the binding of 125 I-scuPA to cell-associated wild type DII-DIII in a dose-dependent, saturable and PI-PLC sensitive manner, but had no effect on binding to m5A-DII-DIII even at concentrations as high as 400 nM ( Figure 6A ).
Similarly, scuPA (10 nM and 50 nM) increased the binding of 125 I-sDI to cell-associated wild type-DII-DIII, but did not increase binding of sDI to m5A-DII-DIII ( Figure 6B ).
The same results were obtained when DI and DII-DIII were co-incubated in solution. shown in Figure 6 . The data from the 120 minute point for each combination of fragments is shown in Figure 7B (mean ± SD, n=3). 
Discussion
It is generally accepted that all three domains of uPAR are required for scuPA to bind with high affinity. This conclusion is based on the finding that deleting any domain from uPAR reduces its affinity for scuPA. For example, scuPA binds with low affinity to either isolated soluble domain I, to soluble domain III or fragments composed of domains I and II or II and III [14] [15] [16] . Co-incubation of scuPA with the receptor fragments only partially restores its affinity when compared with full-length receptor. Our data suggest that all 5 amino acids that we mutated in the loop 2 region of domain II of uPAR participate in the binding process. Furthermore, the competitioninhibition and surface plasmon resonance studies demonstrate that the impact of the two sets of mutations is coordinate and interactive. This conclusion is based on the finding that the mutation of K 139 and H 143 primarily affects the "off rate", whereas mutation of the three arginines perturbs the "on-rate" as well. The fact that mutation of each of the 5 amino acids individually has no discernable effect suggests that the function of certain of these charged residues can compensate for the others. The reduced capacity of the K 139 /H 143 variant m2A-suPAR to stimulate the activity of scuPA was proportional to its lowered binding affinity. In contrast, m3A-suPAR in which R 137 /R 142 /R 145 were altered caused little or no activation of scuPA even under conditions where binding was demonstrable, suggesting these three arginine residues participate in the activation process as well.
It has been suggested that when scuPA binds to uPAR, both components of the complex undergo conformational changes that are involved in cell adhesion, signal transduction and the induction of enzymatic activity 2,27,33 . The R 137 -R 145 sequence might participate in this re-arrangement process to stabilize high affinity binding. This possibility is supported by the finding that the mutation m2A and m3A affects the "off rate" of the interaction. The fact that the three arginines in DII that are mutated in m3A also appear to be essential for activation suggests that additional re-arrangements in the components of the complex are required for post receptor binding event to occur. Clearly, more extensive structural and biophysical (e.g. calorimetric) analyses will be required to elucidate the nature of this complex process.
We have previously shown that uPAR is composed of two major functional units consisting of DI and DII-DIII, which exert a synergistic effect on scuPA binding and activation 14 . This data has since been confirmed 15 Although this study did not distinguish between these two possibilities, R 137 -R 145 is clearly required for the formation of the ternary complex. Additional studies will also be required to establish the pattern and sequence by which the ternary complex is formed. Table 1 legend: The IC 50 (mean ± SD) for each form of uPAR was calculated from three separate inhibition experiments, each performed in triplicate. The experiments were performed as described in the legend to Figure 3 . Table 2 legend: Kinetics of scuPA binding to suPAR measured as surface plasmon resonance. scuPA binding to recombinant suPAR was measured using a BIA 3000
optical Biosensor (Biacore, AB, Sweden). WT-suPAR, m2A-suPAR, m3A-suPAR and m5A-suPAR were coupled individually to a CM5-research grade sensor chip flow cell at a density of 500 RU. Binding of various concentrations of scuPA in PBS, pH=7.4, 0.005% tween-20, was measured at 25 o C at flow rate of 60 µL/min for 2 min, followed by 2 min of dissociation. The data were fit to a 1:1 Langmuir reaction mechanism using global analysis in the BIA evaluation 3.0 Software (Biacore, AB, Sweden) and the calculated association and dissociation rates were derived. Table 3 by guest on September 1, 2017
